NVO News

Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO

Novo Nordisk A/S (NVO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

Novo Nordisk’s Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S

Philanthropic Partnership Backs Country-Led Research to Guide the Use of AI in Health

Monoclonal Antibodies Competitive Landscape Report 2026: Comprehensive Insights About 180+ Companies and 230+ Drugs by Company, Product, Stage of Development, Route of Administration, Molecule Type

Goodpath Expands Direct-to-Employer and Self-Pay Access to Wegovy Through Novo Nordisk Collaboration